Biopath Ventures
1 Fusionopolis Place #03-20 Galaxis, Singapore, 138522
Overview
BioPath Ventures' mission is to identify emerging opportunities in Life Science Tools and Diagnostics which will impact the global market. We intend to develop an investment and business ecosystem to benefit these companies, our clients and the wider community.
- Total investments
- 1
- Lead investments
- 1
- Investments · 12mo
- 0
- Active investors
- 0
Sector focus
- Biotechnology
Investment portfolio
- One BioMed
Led · Series A · Jul 2019
One BioMed is a Singapore-based healthcare startup founded in 2016 by CEO Dr. Mi Kyoung Park as a spin-off of A*STAR. It is developing platform technologies for diagnostic testing, centered on an automated sample-preparation device that purifies and isolates nucleic acids from a wide variety of samples. The company positions this device as the foundation for next-generation platforms, aiming to integrate molecular diagnostic tools and its proprietary silicon biophotonics sensing technology. Future plans include commercializing the first product and building point-of-care infectious disease detection systems. One BioMed closed a US$5M Series A to support commercialization of its initial product.
Team
No current team members are available.